Released Aug 5, 2021, after the close
10-Q filed Aug 6, 2021, 37 days after period end · 0001636422-21-000068
Q2 2021 · 10-Q
Revenue$59.63M$59.63M +37.8% vs Q2 2020+6.8% vs Q1 2021
Net Income-$35.83M-$35.83M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.80-$0.80 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$32,319,000N/M
Operating Cash Flowderived-$4,845,000N/M
Free Cash Flowderived-$7,101,000N/M
Margins · derived
Operating margin-54.2%−18.0 pt vs Q2 2020
Net margin-60.1%+2.7 pt vs Q2 2020
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $59.63M | $43.26M | $36.80M | $22.99M |
| Net Income | -$35.83M | -$27.18M | -$10.69M | -$19.32M |
| EPS Diluted | -$0.80 | -$0.71 | -$21.98 | -$3.53 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR